Senseonics Holdings (SENS) has been beaten down lately with too much selling pressure. While the stock has lost 5.7% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier.We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator that measures the speed and change ...

GERMANTOWN, Md., June 04, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced it will host an in-person and virtual analyst event in conjunction with the American Diabetes Association 85th Scientific Sessions (ADA 2025), on Saturday, June 21, 2025 at 8:00am CT at the Marriot Marquis Chicago. To register ...

Core Viewpoint - Senseonics Holdings, Inc. has successfully closed a public offering of 115 million shares at a price of $0.50 per share, raising gross proceeds of $57.5 million before expenses [1][2]. Group 1: Public Offering Details - The public offering included the full exercise of an option by underwriters to purchase an additional 15 million shares [1]. - The offering was conducted under a "shelf" registration statement that became effective on September 12, 2023 [5]. - The offering was managed by TD Cowen and Barclays as joint book-running managers, with RBC Capital Markets and Lake Street as bookrunners [4]. Group 2: Private Placement with Abbott Laboratories - In conjunction with the public offering, Senseonics entered into a stock purchase agreement with Abbott Laboratories, issuing shares representing 4.99% of its outstanding common stock [3]. - Abbott acquired 40,539,265 shares for approximately $20.3 million before offering expenses [3]. Group 3: Use of Proceeds - The net proceeds from both the public offering and private placement will be used to fund the launch of Eversense 365, ongoing product development, working capital, and general corporate purposes [4][9]. Group 4: Company Overview - Senseonics is focused on developing long-term implantable continuous glucose monitoring systems aimed at improving the lives of individuals with diabetes [7]. - The company's Eversense® CGM systems feature a small sensor that is implanted under the skin and communicates with a smart transmitter, sending glucose data to a mobile app every 5 minutes [7].

Core Insights - Senseonics has been under observation for several years, with a previous bullish article published in March 2021, which did not yield the expected positive results for investors [1] - The investment strategy employed focuses on a value-oriented approach while incorporating reasonably valued growth stocks, emphasizing the importance of buying quality companies at fair prices [1] - The portfolio has shown significant performance variations over the years, with a total return of 4,114% since inception in 2016, and an internal rate of return (IRR) of 51.54% per year [1] Portfolio Performance Summary - 2016: Portfolio return of 1.28%, compared to NASDAQ's 7.50%, resulting in a delta of -6.22% [1] - 2017: Portfolio return of 49.40%, NASDAQ at 28.23%, delta of +21.17% [1] - 2018: Portfolio return of 84.91%, NASDAQ at -3.88%, delta of +88.79% [1] - 2019: Portfolio return of -1.08%, NASDAQ at 35.23%, delta of -36.31% [1] - 2020: Portfolio return of 173.62%, NASDAQ at 43.63%, delta of +129.99% [1] - 2021: Portfolio return of 37.84%, NASDAQ at 21.40%, delta of +16.44% [1] - 2022: Portfolio return of 20.93%, NASDAQ at -33.10%, delta of +54.03% [1] - 2023: Portfolio return of 87.60%, NASDAQ at 43.42%, delta of +44.18% [1] - 2024: Portfolio return of 77.98%, NASDAQ at 29.83%, delta of +48.15% [1]

GERMANTOWN, Md., May 15, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced the pricing of an underwritten public offering of 100,000,000 shares of common stock at a price to the public of $0.50 per share of common stock. The gross proceeds to Senseonics from the offering, before deducting underwriting ...

GERMANTOWN, Md., May 15, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell shares of its common stock. In connection with the proposed offering, Senseonics also expects to grant the underwr ...

Senseonics Holdings (SENS) came out with a quarterly loss of $0.02 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.03 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this medical technology company would post a loss of $0.03 per share when it actually produced a loss of $0.02, delivering a surprise of 33.33%.Over the last four quarters, the company has surpassed consensus EPS estimates just once.Senseonics, which b ...

Senseonics (SENS) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Company Participants Jeremy Feffer - Managing DirectorTimothy Goodnow - President & Chief Executive OfficerRick Sullivan - CFOAnthony Petrone - Managing Director Equity Research Conference Call Participants Sam Eiber - Vice President and Medical Technology Analyst Operator Please stand by. Your program is about to begin. Good day, everyone, and welcome to the Senseonics First Quarter twenty twenty five Earnings Call. At this time, all particip ...

Senseonics (SENS) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Speaker0 Please stand by. Your program is about to begin. Good day, everyone, and welcome to the Senseonics First Quarter twenty twenty five Earnings Call. At this time, all participants are in a listen only mode. Later, you will have the opportunity to ask questions during the question and answer session. You may register to ask questions by pressing the star and one on your telephone keypad. You may withdraw your question by pressing star, t ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission file number: 001-37717 Senseonics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware ...